Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Qiagen Acquires Diagnostics Maker

by Michael McCoy
September 28, 2009 | A version of this story appeared in Volume 87, Issue 39

Qiagen, a Dutch assay technology company, has acquired DxS, a diagnostics firm, for $95 million in cash, plus up to $35 million more if certain milestones are met. Based in Manchester, England, DxS develops molecular diagnostic assays that allow oncologists to predict patient response to cancer treatments. Qiagen says DxS’s products work well with its own automation instruments.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.